Abstract |
Botulinum toxin type A (BTX-A) has been used to treat urethral and prostatic diseases ( off-label uses). Injection of BTX-A into the external sphincter of patients with detrusor external sphincter dyssynergia has been shown to successfully lower postvoid residual volumes and detrusor pressures. Average efficacy is 3 to 4 months, but long-term effects on detrusor leak point pressures or renal function are unknown. Injection of BTX-A into the prostate has shown promising short-term results (< or = 12 months) in improving the symptoms, postvoid residual volumes, maximal urinary flow rates, and prostate sizes in patients with benign prostatic hyperplasia. The mechanisms of action and long-term durability of this treatment modality are unknown. Evidence supporting the use of BTX-A in treating detrusor hypocontractility, pelvic floor dysfunction, postpubovaginal sling retention, urethral stricture, prostatitis, and chronic pelvic pain syndrome in men is preliminary and deserves further evaluation.
|
Authors | H Henry Lai, Christopher P Smith |
Journal | Current urology reports
(Curr Urol Rep)
Vol. 8
Issue 5
Pg. 351-8
(Sep 2007)
ISSN: 1534-6285 [Electronic] United States |
PMID | 17880832
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Aged
- Botulinum Toxins, Type A
(therapeutic use)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Humans
- Injections, Intralesional
- Male
- Middle Aged
- Patient Satisfaction
- Prognosis
- Prostatic Diseases
(diagnosis, drug therapy)
- Risk Assessment
- Severity of Illness Index
- Treatment Outcome
- Urethral Diseases
(diagnosis, drug therapy)
|